Skip to main content
. 2019 Apr 15;11:3253–3264. doi: 10.2147/CMAR.S193793

Figure 6.

Figure 6

CDKN3-regulated cisplatin chemoresistance by RAD51. (A) The results of western blot analyses demonstrated the effective ectopic expression of Rad51 in EC109R/shCDKN3 cells and OE19R/shCDKN3 cells. (BC) Cell viability of EC109R/shCDKN3 cells (B) and OE19R/shCDKN3 cells (C) with or without RAD51 ectopic expression. (DE) Apoptosis rate of EC109R/shCDKN3 cells and OE19R/shCDKN3 cells with or without RAD51 overexpression (D) and quantitative results (E). (FG) γH2AX foci counts of EC109R/shCDKN3 cells and OE19R/shCDKN3 cells with or without RAD51 overexpression (F) and quantitative results (G). Scale bar=5 μm. ***P<0.001.

Abbreviations: NC, negative control; RAD51-OE, RAD51 overexpression; EC109R/shCDKN3, CDKN3 inhibited cisplatin-resistant EC109 cells; OE19R/shCDKN3, CDKN3 inhibited cisplatin-resistant OE19 cells; IC50, half maximal inhibitory concentration.